Gossamer Bio 경영진
경영진 기준 점검 2/4
Gossamer Bio CEO는 Faheem Hasnain, Nov2020 에 임명되었습니다 의 임기는 5.5 년입니다. 총 연간 보상은 $2.30M, 28.2% 급여 및 71.8% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $1.11M 가치에 해당하는 회사 주식의 2.36% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4.3 년과 4.9 년입니다.
핵심 정보
Faheem Hasnain
최고경영자
US$2.3m
총 보수
| CEO 급여 비율 | 28.24% |
| CEO 재임 기간 | 5.5yrs |
| CEO 지분 보유율 | 2.4% |
| 경영진 평균 재임 기간 | 4.3yrs |
| 이사회 평균 재임 기간 | 4.9yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 09
GOSS: Upcoming FDA Talks On Phase 3 Data Will Drive Potential Rerating
Narrative Update Gossamer Bio's analyst price targets have been reset sharply lower, with cuts from as high as $12 to as low as $0.30. Analysts are factoring in weaker than expected Phase 3 PROSERA data, a clouded regulatory path for seralutinib in pulmonary arterial hypertension, and added balance sheet and funding uncertainties.내러티브 업데이트 • Apr 22
GOSS: Upcoming FDA Meeting Will Determine Potential Rerating After Phase 3 Setback
Analysts have lowered their average price targets on Gossamer Bio into the low single-digit dollar range, reflecting reduced modeled revenue growth, a higher discount rate, and increased regulatory uncertainty around seralutinib following the recent Phase 3 PROSERA miss and multiple rating downgrades. Analyst Commentary Recent Street research around Gossamer Bio clusters around two themes: how to weigh the mixed seralutinib data against the regulatory risk, and how to factor balance sheet constraints into valuation.
내러티브 업데이트 • Apr 07
GOSS: Regulatory Path And Funding Outlook Will Shape Future Repricing Potential
Narrative Update: Gossamer Bio The average analyst price target for Gossamer Bio has moved sharply lower into the low single digits, with firms citing reduced probabilities of success for seralutinib in pulmonary arterial hypertension, a mixed Phase 3 PROSERA outcome that missed its primary endpoint, and added regulatory and funding uncertainty as key drivers behind the reset. Analyst Commentary Recent Street research around Gossamer Bio has turned more cautious, with several bearish analysts reacting to the Phase 3 PROSERA miss, regulatory uncertainty for seralutinib in pulmonary arterial hypertension, and funding needs.
내러티브 업데이트 • Mar 24
GOSS: Regulatory Meetings On Phase 3 Miss Will Drive Future Rerating Potential
Narrative Update The analyst price target for Gossamer Bio has been reduced, with fair value moving from $15.00 to about $13.43 as analysts factor in a lower assumed probability of success for seralutinib in pulmonary arterial hypertension, heightened regulatory uncertainty after the Phase 3 PROSERA miss, and balance sheet concerns. These factors are partially offset by ongoing expectations for higher revenue growth, stronger profit margins, and a lower future P/E multiple.내러티브 업데이트 • Mar 08
GOSS: Upcoming FDA Meeting And 2026 Data Readouts Will Drive Rerating Potential
Analysts have sharply reduced their average price targets on Gossamer Bio, cutting them from a prior fair value indication of about $9.50 to roughly $3.69. This change reflects reduced confidence in seralutinib's regulatory path and a reevaluation of risk after the PROSERA Phase 3 miss.내러티브 업데이트 • Feb 21
GOSS: Index Additions And Barclays Bullish Coverage Will Support Future Repricing
Analysts have raised their price target on Gossamer Bio to $6.00, citing new bullish coverage that outlines the company’s updated assumptions for risk, growth, margins and future P/E, while maintaining their fair value estimate at $6.00. Analyst Commentary While the updated price target of US$6.00 reflects a constructive view on Gossamer Bio, some research commentary also highlights areas where expectations could be tested.내러티브 업데이트 • Feb 07
GOSS: Index Additions And Bullish Research Coverage Will Support Future Repricing
Analysts have adjusted their price target for Gossamer Bio to US$6.00, with the updated view supported by slightly revised assumptions on discount rate, revenue growth, profit margin and future P/E following fresh bullish Street research coverage. Analyst Commentary While the updated US$6.00 price target reflects constructive views in recent research, not all commentators are aligned with the bullish tone.내러티브 업데이트 • Jan 23
GOSS: Index Additions And February 2026 Data Will Drive Rerating Potential
Analysts have maintained their fair value estimate for Gossamer Bio at US$9.50 per share. They explained that only modest adjustments to assumptions such as the discount rate and future P/E were required, and these did not affect their overall price target view.분석 기사 • Jan 22
Gossamer Bio, Inc.'s (NASDAQ:GOSS) Popularity With Investors Under Threat As Stock Sinks 27%
The Gossamer Bio, Inc. ( NASDAQ:GOSS ) share price has softened a substantial 27% over the previous 30 days, handing...내러티브 업데이트 • Jan 09
GOSS: Index Additions And Updated Assumptions Will Support Bullish Repricing
Analysts have revised their price target on Gossamer Bio to US$6.00, with the unchanged fair value level tied to updated assumptions that include adjusted discount rates, a higher modeled revenue growth rate of 59.16% and a lower future P/E of about 63.33x. These factors together shape their latest view of the share price outlook.Seeking Alpha • Dec 19
Gossamer Bio: High-Risk Binary Approaches
Summary Gossamer Bio is approaching a binary catalyst with the February 2026 PROSERA phase 3 readout for seralutinib in pulmonary arterial hypertension. PROSERA differs from the phase 2 TORREY study, by focusing on 6MWD as the primary endpoint, enrolling higher-risk patients and more patients outside North America. GOSS is also running a trial of seralutinib in those with pulmonary hypertension associated with interstitial lung disease. That trial only got underway in Q4 '25, however. Read the full article on Seeking Alpha내러티브 업데이트 • Dec 14
GOSS: Upcoming Respiratory Congress Data Will Likely Drive Stronger Market Reassessment
Analysts have sharply raised their price target on Gossamer Bio, with fair value estimates climbing from approximately 1.25 to 6.00 per share. They cite expectations for significantly faster revenue growth and a higher future earnings multiple, despite a modest uptick in discount rates and slightly lower projected profit margins.내러티브 업데이트 • Nov 28
GOSS: Improving Market Conviction Will Drive Momentum Into February 2026 Data Release
Analysts have maintained their price target for Gossamer Bio at $9.50 per share, citing increasingly positive sentiment and renewed conviction about seralutinib’s outlook as key clinical milestones approach. Analyst Commentary As key clinical milestones for seralutinib approach, analysts have weighed in with both optimistic and cautious perspectives regarding Gossamer Bio’s future prospects and current valuation.분석 기사 • Nov 25
Gossamer Bio, Inc.'s (NASDAQ:GOSS) 28% Share Price Surge Not Quite Adding Up
Gossamer Bio, Inc. ( NASDAQ:GOSS ) shareholders have had their patience rewarded with a 28% share price jump in the...내러티브 업데이트 • Nov 14
GOSS: Improving Sentiment Will Drive Momentum Ahead of February 2026 Data Readout
Analysts have raised their price target for Gossamer Bio from $8.86 to $9.50. They cite increased conviction in the company's upcoming clinical data and improving market sentiment around its lead drug candidate.분석 기사 • Oct 11
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Gossamer Bio, Inc. ( NASDAQ:GOSS ) shares have retraced a considerable 27% in the last month, reversing a fair amount...내러티브 업데이트 • Sep 11
Phase III Trials And Global Collaborations Will Expand Treatment Horizons
Analysts have raised their price target for Gossamer Bio from $7.75 to $8.86, citing optimism for seralutinib's novel mechanism and market potential in pulmonary hypertension as key drivers. Analyst Commentary Positive outlook on Gossamer Bio's strategy in targeting pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.분석 기사 • Aug 22
Revenues Not Telling The Story For Gossamer Bio, Inc. (NASDAQ:GOSS) After Shares Rise 26%
Despite an already strong run, Gossamer Bio, Inc. ( NASDAQ:GOSS ) shares have been powering on, with a gain of 26% in...새로운 내러티브 • May 18
Phase III Trials And Global Collaborations Will Expand Treatment Horizons
Successful Phase III study enrollment and collaboration enhance market reach, promising revenue growth through potential positive efficacy results and expanded indications.Seeking Alpha • Feb 14
Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Summary Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS’s pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM. Lastly, Gossamer Bio seems to have enough resources to fund both of these trials in 2025. So, I believe its cash runway is sufficient for now. In my view, GOSS is now basically a binary bet on the upcoming Phase 3 data by the end of the year, and for now, it looks reasonably priced relative to its upside potential. Read the full article on Seeking AlphaSeeking Alpha • Sep 10
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
Summary Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and systemic absorption issues, unlike seralutinib, which targets key disease pathways effectively. Tyvaso DPI's success in PH-ILD highlights the unmet need, with Gossamer planning a Phase 3 trial for seralutinib in mid-2025. Seralutinib's potential in PH-ILD and PAH, combined with its safety profile, positions it as a strong contender in the biopharmaceutical market. Read the full article on Seeking Alpha분석 기사 • Aug 14
Brokers Are Upgrading Their Views On Gossamer Bio, Inc. (NASDAQ:GOSS) With These New Forecasts
Shareholders in Gossamer Bio, Inc. ( NASDAQ:GOSS ) may be thrilled to learn that the analysts have just delivered a...Seeking Alpha • Sep 27
Peaking Back In On Gossamer Bio
Summary Today, we look back in on a small biotech company called Gossamer Bio. The company's primary drug candidate is approaching a key trial milestone and analyst firms are currently sanguine on Gossamer's long-term prospects. An investment analysis follows in the paragraphs below. A humble man speaks not of his own humility" - Jeremy Aldana Today, we are shining the spotlight back on Gossamer Bio (GOSS) for the first time since our last article on this small biotech name back in October of last year. The stock trades almost exactly where it was during our last look at it, which given the carnage in the markets here in 2022, counts as a victory. The shares had some insider buying in July within a private placement. No one else on Seeking Alpha has touched on the company since we last revisited it. In addition, the stock has had a wild ride in recent months. Therefore, it seems to be a good time to incorporate developments in 2022 and update our take on Gossamer. An analysis follows below. Seeking Alpha Company Overview: Gossamer Bio is clinical-stage biopharmaceutical concern focused on the development or procurement of therapies in the areas of immunology, inflammation, and oncology. The company is based in San Diego and the stock currently trades at around $12.00 a share and sports an approximate market cap of $1.1 billion. Recent Developments: August Company Presentation The company has a couple of pipeline assets in development. The most important of which is a compound called seralutinib which is also known as GB002. This candidate is targeting Pulmonary Arterial Hypertension, commonly known as PAH. The condition is a function of abnormal cell growth within and around small blood vessels of the lung that move blood from the right side of the heart to the lungs. Despite products on the market to treat this condition, the five-year survival rate is just over 55%. August Company Presentation Seralutinib has Orphan Drug status both in Europe and U.S. for this indication. This candidate is an inhaled inhibitor of the following tyrosine kinases: platelet-derived growth factor receptors α and β (PDGFRs), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. It is designed to treat PAH as described in the slide above. August Company Presentation Currently, seralutinib is being evaluated in a Key Phase 2 trial called Torrey. This is a clinical study in patients with PAH whose disease has progressed despite standard-of-care therapy. The primary endpoint of this trial is the change in pulmonary vascular resistance from baseline at week 24. Topline results are scheduled to be out anywhere from the back half of November or first half of December of this year. August Company Presentation Last week, Wedbush reiterated their Buy rating on GOSS. The analyst there noted: This mid-stage trial has a high likelihood of success due to seralutinib's mechanism of action and positive results in both the preclinical and early-stage studies." She further stated that she 'believes that seralutinib has the potential to capture 42% of the market in the U.S. in 2030 with projected sales of $2.5B, assuming that the drug is launched in 2026.' August Company Presentation The company has a couple of other earlier staged assets in development. The only out of the clinic is GB5121. This is an oral, CNS-Penetrant BTK Inhibitor that is targeting Primary CNS Lymphoma (PCNSL) and other Rare CNS Malignancies. Currently, an open-label Phase 1b/2 study 'STAR' is underway to evaluate GB5121 for these indications. That study recently dosed its first patient. Management has stated that data from STAR will be presented at relevant medical conferences, as data become available. August Company Presentation Analyst Commentary & Balance Sheet: The company ended the second quarter with just over $220 million in cash and marketable securities on its balance sheet after posting a net loss for the quarter of $56.5 million. Two weeks after the quarter closed, management executed a private placement that raised an additional $120 million in proceeds. Four insiders including the CEO and CFO bought nearly $1.2 million in total of the private placement in mid-July. Up to that point, insiders had sold approximately $600,000 worth of shares in aggregate in 2022. Just over 20% of the outstanding float in GOSS is currently held short. The company has just over $200 million in long-term debt.Seeking Alpha • Jul 13
Gossamer Bio to raise $120M in a private equity placement
Gossamer Bio (NASDAQ:GOSS) to sell approximately 16.6M shares of its common stock at $7.21/share in a private placement. Gross proceeds are expected to be approximately $120M. The financing is expected to close on July 15. “We are very pleased this high-quality group of investors came together to support the seralutinib program at this important juncture,” said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer. “These additional funds will allow us to accelerate and expand our investment in seralutinib ahead of the Phase 2 TORREY Study topline results in the fourth quarter of this year.” In addition to supporting the seralutinib program, the company intends to use the net proceeds to fund research and development of its other product candidates and development programs and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash, cash equivalents and marketable securities, and access to its debt facility is expected to be sufficient to fund operating and capital expenditures into mid-2024.분석 기사 • Jun 25
Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Jan 19
Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...분석 기사 • Sep 22
Is Gossamer Bio (NASDAQ:GOSS) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...분석 기사 • Jan 28
Need To Know: Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Have Been Buying Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$180m |
| Dec 31 2025 | US$2m | US$650k | -US$170m |
| Sep 30 2025 | n/a | n/a | -US$156m |
| Jun 30 2025 | n/a | n/a | -US$139m |
| Mar 31 2025 | n/a | n/a | -US$51m |
| Dec 31 2024 | US$2m | US$628k | -US$57m |
| Sep 30 2024 | n/a | n/a | -US$72m |
| Jun 30 2024 | n/a | n/a | -US$81m |
| Mar 31 2024 | n/a | n/a | -US$173m |
| Dec 31 2023 | US$2m | US$607k | -US$180m |
| Sep 30 2023 | n/a | n/a | -US$187m |
| Jun 30 2023 | n/a | n/a | -US$207m |
| Mar 31 2023 | n/a | n/a | -US$221m |
| Dec 31 2022 | US$7m | US$592k | -US$229m |
| Sep 30 2022 | n/a | n/a | -US$230m |
| Jun 30 2022 | n/a | n/a | -US$231m |
| Mar 31 2022 | n/a | n/a | -US$234m |
| Dec 31 2021 | US$5m | US$574k | -US$234m |
| Sep 30 2021 | n/a | n/a | -US$242m |
| Jun 30 2021 | n/a | n/a | -US$240m |
| Mar 31 2021 | n/a | n/a | -US$247m |
| Dec 31 2020 | US$1m | US$72k | -US$243m |
| Sep 30 2020 | n/a | n/a | -US$233m |
| Jun 30 2020 | n/a | n/a | -US$224m |
| Mar 31 2020 | n/a | n/a | -US$202m |
| Dec 31 2019 | US$1m | US$200k | -US$180m |
보상 대 시장: Faheem의 총 보수(USD2.30M)는 US 시장에서 비슷한 규모 기업의 평균(USD638.05K)보다 높습니다.
보상과 수익: Faheem의 보상은 회사가 적자임에도 증가했습니다.
CEO
Faheem Hasnain (67 yo)
5.5yrs
재임 기간
US$2,300,455
보수
Mr. Faheem Hasnain is Chairman of the Board of Sling Therapeutics, Inc. He has been Chief Executive Officer and President at Gossamer Bio, Inc. since November 16, 2020. He served as Executive Advisor at Ve...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 5.5yrs | US$2.30m | 2.36% $ 1.1m | |
| COO & CFO | 8yrs | US$1.25m | 0.24% $ 115.1k | |
| Chief Commercial Officer | 2.4yrs | US$1.18m | 0.018% $ 8.5k | |
| Executive VP of Technical Operations & Administration and General Counsel | 4.2yrs | US$1.65m | 0.34% $ 160.3k | |
| Senior Vice President of Marketing | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Human Resources | no data | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | no data | US$1.07m | 0.089% $ 42.1k | |
| Senior Vice President of Clinical Development of Pulmonary Vascular Disease | 1.7yrs | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Regulatory Affairs | 8.1yrs | 데이터 없음 | 0.11% $ 52.1k | |
| Senior Vice President of Biometrics | 5.2yrs | 데이터 없음 | 데이터 없음 | |
| MD & President of Gossamer Bio Ireland | 4.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Program Team Lead | 1.3yrs | 데이터 없음 | 데이터 없음 |
4.3yrs
평균 재임 기간
61yo
평균 나이
경험이 풍부한 관리: GOSS의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 10.6yrs | US$2.30m | 2.36% $ 1.1m | |
| Independent Director | 7.5yrs | US$186.32k | 0.0031% $ 1.4k | |
| Lead Independent Director | 8.3yrs | US$199.57k | 0.016% $ 7.7k | |
| Independent Director | 2.5yrs | US$172.07k | 0% $ 0 | |
| Independent Director | 4.9yrs | US$179.32k | 0.025% $ 11.7k | |
| Independent Director | 2.2yrs | US$167.44k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$181.44k | 0% $ 0 |
4.9yrs
평균 재임 기간
62yo
평균 나이
경험이 풍부한 이사회: GOSS의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.9 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 23:50 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Gossamer Bio, Inc.는 22명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Carter Gould | Barclays |
| Eliana Merle | Barclays |
| Zhilin Long | Berenberg |